Alx Oncology Holdings

Market Cap

$242M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.54+$0.39 (+33.91%)

Jun 5, 2026

52W High $2.6052W Low $0.41

Company Details

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic develop...

CEO

—

IPO Date

Jul 17, 2020

Website

www.alxoncology.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$89M

EPS (Diluted)

Free Cash Flow

-$78M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q2 2026

Aug 11, 2026

PENDING

Q1 2026

May 8, 2026

FY 2025

Mar 9, 2026

Q4 2025

Mar 9, 2026

$0-100.0%

Q3 2025

Nov 7, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee